Anti-HER2 Therapy Beyond Second-Line for HER2- Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel
| Autor: | Pilar Zamora, Noelia Martínez-Jañez, Arrate Plazaola, I. Fernández, José Antonio Ponce, Paula García-Teijido, Ignacio Chacón, Sonia Del Barco, Sonia Servitja, Ana de Juan, Luis Cruz-Merino, Amalia Gómez-Bernal |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment Disease Clinical practice Lapatinib Metastasis 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine 030212 general & internal medicine skin and connective tissue diseases neoplasms Chemotherapy business.industry Metastatic breast cancer medicine.disease Anti-HER2 Blockade Clinical trial chemistry Trastuzumab emtansine 030220 oncology & carcinogenesis Original Article Surgery business medicine.drug |
| Zdroj: | Breast Care r-FISABIO. Repositorio Institucional de Producción Científica instname r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante r-FISABIO: Repositorio Institucional de Producción Científica Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid |
| ISSN: | 1661-3805 1661-3791 |
| Popis: | Background: The aim of this project was to provide an expert opinion regarding anti-human epidermal growth factor receptor 2 (HER2) therapy beyond second-line treatment of metastatic breast cancer (mBC). Methods: A group of experts discussed specific issues concerning anti-HER2 therapy in late-line settings in mBC. Results: Trastuzumab emtansine (T-DM1) or dual HER2 blockade appeared to be good options for HER2-positive mBC after ≥ 2 HER2-targeted therapies. Once an objective response has been achieved with anti-HER2-containing therapy, the anti-HER2 agent can be continued until progression of the disease, unacceptable toxicity or patient decision. mBC treated with ≥ 3 consecutive lines of anti-HER therapy, ≥ 1 being a dual HER2 blockade and with early progression of disease during a fourth or later-line treatment, are clinically resistant to anti-HER therapy. For progression of metastasis in the brain after anti-HER2 therapy, lapatinib and chemotherapy appear to be a good alternative after best local treatment. Conclusions: Further clinical trials are needed to provide valuable knowledge about the best treatment options in the later settings of mBC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|